Scholarlink

Purpose <p>To compare 24-month outcomes of Thulium fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation of the prostate (HoLEP).</p> Methods <p>A 24-month follow-up analysis of a prospective randomized trial including 150 patients (ThuFLEP <i>n</i> = 74, HoLEP <i>n</i> = 76) was conducted. Primary outcome was non-inferior International Prostate Symptom Score (IPSS) and quality of life (QoL) reduction. Secondary outcomes included urinary continence, medication use reduction, erectile and ejaculatory function, and late adverse events.</p> Results <p>At 24 months, non-inferiority of ThuFLEP regarding IPSS and QoL was confirmed (<i>p</i> = 0.03). Median IPSS improved from 21 preoperatively to 3 after ThuFLEP and from 20 to 4 after HoLEP (<i>p</i> &lt; 0.001), with no significant intergroup differences at any time point (all <i>p</i> &gt; 0.1). Median QoL improved from 4 to 1 in both groups (<i>p</i> &lt; 0.001), likewise without significant differences at any time point (all <i>p</i> &gt; 0.3). Continence rates improved from 74.0% preoperatively to 90.0%, pad usage decreased from 89.8% to 25.4% and ICIQ-SF decreased from 5 to 3 points (all <i>p</i> &lt; 0.001), without intergroup differences (all <i>p</i> &gt; 0.1). Use of medication for lower urinary tract symptoms decreased from 89.4% to 7.7% (<i>p</i> &lt; 0.001). Ejaculatory function declined, while ejaculation-related bother remained unchanged and erectile function improved modestly, all without intergroup differences (all <i>p</i> &gt; 0.1). Three late adverse events occurred exclusively in the ThuFLEP group, without statistical significance (<i>p</i> &gt; 0.1).</p> Conclusion <p>ThuFLEP remains non-inferior to HoLEP for patient-reported functional outcomes at 24 months and demonstrates comparable safety, continence, medication use reduction, and sexual function results over time. Both techniques represent effective, durable and safe surgical options for treating benign prostatic obstruction.</p> Trial Registration Number <p>DRKS00032699 (18.09.2023, retrospectively registered).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Maximilian Filzmayer,
  • Cristina Cano Garcia,
  • Miriam I. Traumann,
  • Matthias J. Müller,
  • Clara Humke,
  • Philipp C. Mandel,
  • Luis A. Kluth,
  • Andreas Becker,
  • Felix K.-H. Chun,
  • Marina Kosiba

摘要

Purpose

To compare 24-month outcomes of Thulium fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation of the prostate (HoLEP).

Methods

A 24-month follow-up analysis of a prospective randomized trial including 150 patients (ThuFLEP n = 74, HoLEP n = 76) was conducted. Primary outcome was non-inferior International Prostate Symptom Score (IPSS) and quality of life (QoL) reduction. Secondary outcomes included urinary continence, medication use reduction, erectile and ejaculatory function, and late adverse events.

Results

At 24 months, non-inferiority of ThuFLEP regarding IPSS and QoL was confirmed (p = 0.03). Median IPSS improved from 21 preoperatively to 3 after ThuFLEP and from 20 to 4 after HoLEP (p < 0.001), with no significant intergroup differences at any time point (all p > 0.1). Median QoL improved from 4 to 1 in both groups (p < 0.001), likewise without significant differences at any time point (all p > 0.3). Continence rates improved from 74.0% preoperatively to 90.0%, pad usage decreased from 89.8% to 25.4% and ICIQ-SF decreased from 5 to 3 points (all p < 0.001), without intergroup differences (all p > 0.1). Use of medication for lower urinary tract symptoms decreased from 89.4% to 7.7% (p < 0.001). Ejaculatory function declined, while ejaculation-related bother remained unchanged and erectile function improved modestly, all without intergroup differences (all p > 0.1). Three late adverse events occurred exclusively in the ThuFLEP group, without statistical significance (p > 0.1).

Conclusion

ThuFLEP remains non-inferior to HoLEP for patient-reported functional outcomes at 24 months and demonstrates comparable safety, continence, medication use reduction, and sexual function results over time. Both techniques represent effective, durable and safe surgical options for treating benign prostatic obstruction.

Trial Registration Number

DRKS00032699 (18.09.2023, retrospectively registered).